Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2015-001760-19-NL
EUCTR2015-001760-19-NLActive, not recruitingPhase 1

A double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events

Theracos Sub, LLC0 sites1,650 target enrollmentStarted: December 22, 2015Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Sponsor
Enrollment
1,650
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
All

Inclusion Criteria

  • •The study population will include:
  • •1. Male or female adult subjects with an age =40 years
  • •2. Subjects with a diagnosis of T2DM
  • •3. Subjects with HbA1c values of 7.0 – 11%, inclusive
  • •4. Subjects with fasting plasma glucose (FPG) = 300 mg/dL at screening
  • •5. Subjects who have a regimen for treatment of T2DM that has been stable for the past 3 months. A stable regimen is defined as: no changes in dose or frequency of OHAs or GLP-1 agonists, or < 20% variability in total daily insulin dose.
  • •6. Subjects who present with at least one of the following 3 histories:
  • •Group 1: A history of atherosclerotic vascular disease as defined by one or more of the following:
  • •a) myocardial infarction (MI) or ischemic (non-hemorrhagic) stroke
  • •> 3 months but = 5 years prior to screening or
  • •b) documented history of coronary, carotid, or peripheral arterial revascularization (coronary artery bypass grafting must have occurred = 5 years prior to screening)
  • •Group 2: A history of NYHA class II or class III heart failure (Appendix 4) at the time of screening. A history of heart failure is defined as:
  • •documented left ventricular ejection fraction (LVEF) = 40% and no subsequent LVEF > 40% within 6 months of screening, or
  • •(i) an NT-proBNP >300 pg/mL and no evidence of atrial fibrillation/flutter (AF) at the time of the screening ECG or an NT-proBNP >900 pg/mL and evidence of AF at the time of the screening ECG and (ii) either (a) structural heart disease documented by report of left atrial enlargement or left ventricular hypertrophy, or (b) exhibiting symptom(s) of HF requiring treatment with diuretic(s) for at least 30 days prior to screening.
  • •Group 3: Age = 55 years with 2 or more of the following:
  • •a) diabetes duration of = 10 years,
  • •b) uncontrolled hypertension defined as SBP > 140 mmHg despite 3 or more anti-hypertensive medications
  • •c) current smoking,
  • •d) urine albumin:creatinine ratio (UACR) > 30 mg/g,
  • •e) eGFR of 45 to 60 mL/min/1.73 m2, or
  • •f) HDL < 1 mmol/L (38 mg/dL)
  • •7. Female subjects of childbearing potential who are willing to use an adequate method of contraception and to not become pregnant for the duration of the study. Adequate contraceptive measures include, but are not limited to, oral contraceptives, intrauterine devices, Depo-Provera, Norplant, hormonal contraceptive implants, bilateral tubal ligation, partner with vasectomy, condom or diaphragm plus contraceptive sponge, foam, or jelly, and abstinence
  • •8. Subjects who are willing and able to return for all clinic visits and to complete all study required procedures, including self-monitored blood glucose (SMBG) measurement, and take run-in medication, missing no more than one dose due to non-compliance.
  • •9. Subjects who receive anti-hypertensive medications at a stable dosage for = 2 weeks prior to randomization
  • •10. Subjects who receive lipid modifying therapy on a stable regimen for 6 weeks prior to randomization
  • •11. Subjects who have seated SBP < 170 mmHg and DBP < 110 mmHg at screening.
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 825
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 825

Exclusion Criteria

  • •Patients who exhibit any of the following characteristics will be excluded from the study.
  • •1. Diagnosis of type 1 diabetes mellitus or maturity–onset/diabetes of the young (MODY)
  • •2. Hemoglobinopathy that affects HbA1c measurement
  • •3. Frequent symptomatic hypoglycemia (greater than one episode per week on average)
  • •4. Genitourinary tract infection within 6 weeks of screening or history of = 3 genitourinary infections requiring treatment within the last 6 months
  • •5. Cancer, active or in remission for < 3 years (Non-melanoma skin cancer or basal cell carcinoma or carcinoma in situ of the cervix will not be grounds for exclusion)
  • •6. History of alcohol or illicit drug abuse in the past 2 years
  • •7. Evidence of abnormal liver function tests (total bilirubin or alkaline phosphatase > 1.5 x upper limit of normal (ULN) with the exception of isolated Gilbert’s syndrome); or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 x ULN
  • •8. History of MI, stroke or hospitalization for heart failure in the prior 3 months
  • •9. Evidence of NYHA class IV heart failure at screening or randomization
  • •10. Presently scheduled for percutaneous coronary intervention, coronary artery bypass grafting or any surgical procedure
  • •11. Previous treatment with bexagliflozin or EGT0001474
  • •12. Currently or within 3 months of taking any SGLT2 inhibitors
  • •13. Any condition, disease, disorder, or clinically relevant laboratory abnormality that, in the opinion of the PI, would jeopardize the subject’s appropriate participation in this study or obscure the effects of treatment
  • •14. Prior renal transplantation or evidence of nephrotic syndrome, defined as a urine albumin: creatinine ratio (UACR) > 2000 mg/g, at screening
  • •15. Implantation of a cardiac resynchronization therapy device within 3 months prior to screening or intent to implant a cardiac resynchronization therapy (CRT) within 6 months following screening
  • •16. Diagnosis of peripartum or chemotherapy-induced cardiomyopathy within 12 months prior to screening
  • •17. Symptomatic bradycardia or second or third degree atrioventricular block without a pacemaker
  • •18. eGFR, as calculated by the modification of diet in renal disease study equation (MDRD), < 45 mL/min/1.73 m2 or requiring dialysis
  • •19. Pregnant or nursing
  • •20. Currently participating in another interventional trial.

Investigators

Sponsor
Theracos Sub, LLC

Similar Trials

Completed
Phase 3
A double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse eventsType 2 diabetes and increased risk of cardiovascular adverse events100192801001842410003216
NL-OMON47856Theracos Sub, LLC132
Active, not recruiting
Phase 1
A clinical trial in patients with type II diabetes with increased risk of cardiovascular events (incidents that may cause damage to the heart muscle), to study how well a person’s diabetes is controlled over a 2-3 month period with bexagliflozin, by measuring blood sugar levels using a HbA1c test, and to determine safety by assessing occurrence of cardiovascular events.Type II diabetesMedDRA version: 20.1 Level: LLT Classification code 10045242 Term: Type II diabetes mellitus System Organ Class: 100000004861
EUCTR2015-001760-19-DKTheracos Sub, LLC1,650
Active, not recruiting
Phase 1
A clinical trial in patients with type II diabetes with increased risk of cardiovascular events (incidents that may cause damage to the heart muscle), to study how well a person’s diabetes is controlled over a 2-3 month period with bexagliflozin, by measuring blood sugar levels using a HbA1c test, and to determine safety by assessing occurrence of cardiovascular events.Type II diabetesMedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861
EUCTR2015-001760-19-PLTheracos Sub, LLC1,650
Active, not recruiting
Phase 1
A double blind placebo controlled study to evaluate the effect ofbexagliflozin tablets on hemoglobin A1c in patients with type 2diabetes mellitus and moderate renal impairment
EUCTR2016-002580-34-ESTheracos Sub, LLC300
Active, not recruiting
Phase 1
A clinical trial in patients with type II diabetes with increased risk of cardiovascular events (incidents that may cause damage to the heart muscle), to study how well a person’s diabetes is controlled over a 2-3 month period with bexagliflozin, by measuring blood sugar levels using a HbA1c test, and to determine safety by assessing occurrence of cardiovascular events.Type II diabetesMedDRA version: 18.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861
EUCTR2015-001760-19-DETheracos Sub, LLC1,700
A clinical trial in patients with type II... | Clinical Trial